FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564214331> ?p ?o ?g. }

• W2564214331 abstract "Abstract Abstract 4385 Introduction: Successful autologous peripheral blood stem cell transplantation (aPBSCT) is critical for long-term survival and quality of life in patients with multiple myeloma (MM). Standard mobilization of PBSCs is in 15 to 20% of MM patients inefficient. Better mobilization response is achieved by adding plerixafor to current mobilization regimens. Based on studies it is possible to reduce these numbers to 2%. Methodology: During the period from 06/2009 to 08/2011 our department mobilized five patients with MM using plerixafor, of whom three were remobilized using standard G-CSF + plerixafor scheme (G+P) after a previous unsuccessful mobilization with cyclophosphamide + G-CSF (C+G). Two patients received plerixafor on demand in a failed first-line mobilization attempt (C+G+P). Comprehensive statistical analysis of products mobilized with plerixafor (8 products) versus products obtained using C+G regime alone (40 products) was performed comparing smears, colony forming-units (CFUs) and immunophenotype profile. Time to mobilization, pretreatment, used mobilization regime and adverse effects of plerixafor regimes were also analyzed. The ultimate goal of every mobilization - successful transplantation - was also described and analyzed comparing composition of transplanted products with engraftment of white blood cells (WBC), neutrophil granulocytes and platelets. Results: Analysis of the plerixafor group only: 1. Both mobilization strategies (second-line G+P and first-line C+G+P) allowed to collect enough CD34+ cells for one (3 patients) or two (2 patients) transplants. Failure to mobilize using plerixafor has not been recorded. 3 patients successfully received transplants. 2. Based on an analysis of risk factors for determining poor mobilizer 3 patients could be mobilized preemptively using G+P scheme preventing use of controversial cyclophosphamide. 3. Adverse effects were mild and mainly related to G-CSF. In one patient mobilization was stopped after collecting 2.45 ×106/kg because of anxiety. However, we were unable to definitely connect anxiety symptoms to plerixafor. 4. There was a statistically significant increase of leukocytes in peripheral blood observed after adding plerixafor. In 3 patients it allowed the CD34+ cells to rise above 20/μl. Comparative analysis of plerixafor group vs. group of patients mobilized with C+G: 1. Duration of cytopenia after transplantation was comparable and statistically not different. 2. Significantly higher numbers of CD19+ cells after plerixafor administration suggest a possible value of this drug in the treatment of diseases with this marker. 3. Significant reduction of toxic granulation after plerixafor administration may be a proof of lesser number of infectious complications. 4. Significantly lower numbers of younger cell forms and non-significantly higher numbers of mature cells in products mobilized with plerixafor prove a) no cytotoxic effect of plerixafor b) decreased regenerative potential of bone marrow in poor mobilizers even if chemotherapy is used. 5. Significantly lower numbers of CD34+ cells and CFUs in plerixafor mobilized products suggest a worse overall mobilization response in this group. However CFUs have shown to predict stem cells yield better than CD34+ cells alone. 6. The importance of a non-significant decrease in CD56+ cells in plerixafor mobilized products is unclear as co-expression of CD 38/56 does not show any differences. Conclusions: 1. Preemptive first line mobilization with G+P seems to be an important strategy in predicted poor mobilizers which would otherwise be mobilized with C+G(+P). This prevents possible neutropenia and its complications. On demand first line G+P seems to be a good choice in patients that are mobilized with growth factors only as there is no risk of neutropenia. 2. We highly recommend the investigation of CFUs which usually predict stem cells yield better than CD34+ cells alone and may allow transplantation even if CD34+ cells are low. 3. Because aPBSCT is a therapeutic modality with clear benefit for patients with MM, we highly recommend the use of plerixafor in all MM patients where it is impossible to collect sufficient stem cells. According to our investigation, we believe that plerixafor is only starting its career as a mobilization drug. Its most valuable potential may be in curative regimens of diseases which have affinity to bone marrow. Disclosures: No relevant conflicts of interest to declare." @default.
• W2564214331 created "2017-01-06" @default.
• W2564214331 creator A5001255563 @default.
• W2564214331 creator A5006834567 @default.
• W2564214331 creator A5007068928 @default.
• W2564214331 creator A5018415606 @default.
• W2564214331 creator A5023869329 @default.
• W2564214331 creator A5041894113 @default.
• W2564214331 creator A5054179115 @default.
• W2564214331 creator A5070000134 @default.
• W2564214331 creator A5084859550 @default.
• W2564214331 date "2011-11-18" @default.
• W2564214331 modified "2023-09-29" @default.
• W2564214331 title "Two Strategies of Stem Cells Mobilization Using Plerixafor and Comparison of Grafts Obtained with and without It. Is Plerixafor Only a Mobilization Agent?" @default.
• W2564214331 doi "https://doi.org/10.1182/blood.v118.21.4385.4385" @default.
• W2564214331 hasPublicationYear "2011" @default.
• W2564214331 type Work @default.
• W2564214331 sameAs 2564214331 @default.
• W2564214331 citedByCount "0" @default.
• W2564214331 crossrefType "journal-article" @default.
• W2564214331 hasAuthorship W2564214331A5001255563 @default.
• W2564214331 hasAuthorship W2564214331A5006834567 @default.
• W2564214331 hasAuthorship W2564214331A5007068928 @default.
• W2564214331 hasAuthorship W2564214331A5018415606 @default.
• W2564214331 hasAuthorship W2564214331A5023869329 @default.
• W2564214331 hasAuthorship W2564214331A5041894113 @default.
• W2564214331 hasAuthorship W2564214331A5054179115 @default.
• W2564214331 hasAuthorship W2564214331A5070000134 @default.
• W2564214331 hasAuthorship W2564214331A5084859550 @default.
• W2564214331 hasConcept C126322002 @default.
• W2564214331 hasConcept C129470790 @default.
• W2564214331 hasConcept C13373296 @default.
• W2564214331 hasConcept C141071460 @default.
• W2564214331 hasConcept C156708679 @default.
• W2564214331 hasConcept C166957645 @default.
• W2564214331 hasConcept C170493617 @default.
• W2564214331 hasConcept C2778828106 @default.
• W2564214331 hasConcept C2911091166 @default.
• W2564214331 hasConcept C71924100 @default.
• W2564214331 hasConcept C95457728 @default.
• W2564214331 hasConceptScore W2564214331C126322002 @default.
• W2564214331 hasConceptScore W2564214331C129470790 @default.
• W2564214331 hasConceptScore W2564214331C13373296 @default.
• W2564214331 hasConceptScore W2564214331C141071460 @default.
• W2564214331 hasConceptScore W2564214331C156708679 @default.
• W2564214331 hasConceptScore W2564214331C166957645 @default.
• W2564214331 hasConceptScore W2564214331C170493617 @default.
• W2564214331 hasConceptScore W2564214331C2778828106 @default.
• W2564214331 hasConceptScore W2564214331C2911091166 @default.
• W2564214331 hasConceptScore W2564214331C71924100 @default.
• W2564214331 hasConceptScore W2564214331C95457728 @default.
• W2564214331 hasLocation W25642143311 @default.
• W2564214331 hasOpenAccess W2564214331 @default.
• W2564214331 hasPrimaryLocation W25642143311 @default.
• W2564214331 hasRelatedWork W1495479262 @default.
• W2564214331 hasRelatedWork W1572109053 @default.
• W2564214331 hasRelatedWork W1646927778 @default.
• W2564214331 hasRelatedWork W1937995470 @default.
• W2564214331 hasRelatedWork W1964423088 @default.
• W2564214331 hasRelatedWork W2010104223 @default.
• W2564214331 hasRelatedWork W2034776183 @default.
• W2564214331 hasRelatedWork W2040239160 @default.
• W2564214331 hasRelatedWork W2044242415 @default.
• W2564214331 hasRelatedWork W2112158875 @default.
• W2564214331 hasRelatedWork W2147730536 @default.
• W2564214331 hasRelatedWork W2185365349 @default.
• W2564214331 hasRelatedWork W2552592152 @default.
• W2564214331 hasRelatedWork W2560415730 @default.
• W2564214331 hasRelatedWork W2572084376 @default.
• W2564214331 hasRelatedWork W2586690008 @default.
• W2564214331 hasRelatedWork W2890351594 @default.
• W2564214331 hasRelatedWork W2980236951 @default.
• W2564214331 hasRelatedWork W3134162365 @default.
• W2564214331 hasRelatedWork W952754205 @default.
• W2564214331 isParatext "false" @default.
• W2564214331 isRetracted "false" @default.
• W2564214331 magId "2564214331" @default.
• W2564214331 workType "article" @default.